The explosion of GLP-1 weight loss drugs is reminiscent of the early days of PD-1 inhibitors, but key market differences ...

People without diabetes can lose up to 13% of their starting weight in 6 months using tirzepatide (Mounjaro) as an off-label ...

The self-styled sommelier of horror wants to create new franchises and new characters, push boundaries, and give fans a slice of the bloody pie: "What matters in horror is the intellectual property." ...

During a health-focused event in New York on Tuesday, Google announced that it's developing a collection of "open" AI models ...

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

A rise in the use of non-FDA-approved diabetes and obesity medications has spurred health care professionals and medical ...

On this episode of The Vet Blast Podcast presented by dvm360, Adam Christman, DVM, MBA, and Tyler Primavera, DVM, explore the ...

Roche (RHHBY) is increasing its investment into the obesity space with an up to $5.3 billion deal with Danish drugmaker Zealand Pharma (ZLDPF), the companies announced Wednesday. The deal would give ...

Burke Wealth Management, an investment management company, released its “Focused Growth Strategy” fourth quarter 2024 ...

Eli Lilly & Co. said Tuesday it’s cutting the ... It said it will also be adding two new doses, as competition in the space continues to heat up. The move came just days after a regulatory ...